By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Siemens Healthcare Diagnostics today announced two deals to develop companion diagnostics for candidate drugs currently in clinical trials.

One deal with ViiV Healthcare focuses on ViiV's Celsentri/Selzentry (maraviroc) AIDS therapy. The other with Tocagen is targeted at that firm's gene therapy for treating primary brain cancer.

Financial details were not disclosed for either deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.